Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00656305 · ClinicalTrials.gov registry record · NA
ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain
A NA study, sponsored by InSightec.
- Completed
- Registry status
- NA
- Development phase
- 147
- Enrollment target
NCT00656305: Completed NA study, sponsored by InSightec.
NCT00656305 is a NA study that has completed, run by InSightec. The registered enrollment target is 147 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00656305, a NA study, has completed, sponsored by InSightec.
- COMPLETED
- Registry status
- NA
- Development phase
- 147 participants
- Enrollment target
Study Summary
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone and Multiple Myeloma Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
Primary Outcome
Using the Numerical Rating Score (NRS) for pain (0 being no pain and 10 being worst imaginable pain), each subject was rated as a Responder or Non-responder. A responder is defined as a subject with a reduction in NRS worst score from baseline of two (2) or more points, and no increase in pain medication use.
Interventions
- DEVICE Sham
- DEVICE ExAblate MRfFUS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2008-03 |
| Est. Completion | 2012-09 |
| Phase | NA |
What the finished NCT00656305 record still lists
NCT00656305 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.
NCT00656305 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00656305 about?
NCT00656305 is a clinical study titled "ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain". A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone and Multiple Myeloma Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
What is the current status of trial NCT00656305?
This trial is currently completed. It is a NA study. The enrollment target is 147 participants. The study started on 2008-03. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00656305?
The interventions under investigation include: Sham (DEVICE), ExAblate MRfFUS (DEVICE).
Who is sponsoring clinical trial NCT00656305?
This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00656305's enrollment target sits among peer trials
147 703rd of 2000 higher than 1,297 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia